vs
华利安（HLI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是华利安的1.1倍（$772.1M vs $717.1M），华利安净利率更高（16.3% vs 12.7%，领先3.5%），华利安同比增速更快（13.0% vs 5.9%），华利安自由现金流更多（$217.0M vs $161.8M），过去两年华利安的营收复合增速更高（17.4% vs 9.0%）
华利安是美国知名跨国独立投资银行及金融服务机构，1972年成立，总部位于加利福尼亚州洛杉矶世纪城的星座广场。公司为上市企业、非公众公司、机构及政府主体提供专业服务，核心业务涵盖并购咨询、资本解决方案、重组与困境并购、公允意见出具，以及财务与估值顾问等领域。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HLI vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$717.1M
营收增速更快
HLI
高出7.2%
5.9%
净利率更高
HLI
高出3.5%
12.7%
自由现金流更多
HLI
多$55.3M
$161.8M
两年增速更快
HLI
近两年复合增速
9.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $717.1M | $772.1M |
| 净利润 | $116.5M | $98.4M |
| 毛利率 | 32.2% | — |
| 营业利润率 | 22.4% | 14.5% |
| 净利率 | 16.3% | 12.7% |
| 营收同比 | 13.0% | 5.9% |
| 净利润同比 | 22.3% | 3.9% |
| 每股收益（稀释后） | $1.70 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HLIRVTY
| Q4 25 | $717.1M | $772.1M | ||
| Q3 25 | $659.5M | $698.9M | ||
| Q2 25 | $605.3M | $720.3M | ||
| Q1 25 | $666.4M | $664.8M | ||
| Q4 24 | $634.4M | $729.4M | ||
| Q3 24 | $575.0M | $684.0M | ||
| Q2 24 | $513.6M | $691.7M | ||
| Q1 24 | $520.5M | $649.9M |
净利润HLIRVTY
| Q4 25 | $116.5M | $98.4M | ||
| Q3 25 | $111.8M | $46.7M | ||
| Q2 25 | $97.5M | $53.9M | ||
| Q1 25 | $121.9M | $42.2M | ||
| Q4 24 | $95.3M | $94.6M | ||
| Q3 24 | $93.5M | $94.4M | ||
| Q2 24 | $88.9M | $55.4M | ||
| Q1 24 | $81.1M | $26.0M |
毛利率HLIRVTY
| Q4 25 | 32.2% | — | ||
| Q3 25 | 33.8% | 53.6% | ||
| Q2 25 | 31.0% | 54.5% | ||
| Q1 25 | 33.9% | 56.5% | ||
| Q4 24 | 31.4% | — | ||
| Q3 24 | 33.0% | 56.3% | ||
| Q2 24 | 30.6% | 55.7% | ||
| Q1 24 | 30.3% | 54.6% |
营业利润率HLIRVTY
| Q4 25 | 22.4% | 14.5% | ||
| Q3 25 | 22.9% | 11.7% | ||
| Q2 25 | 14.8% | 12.6% | ||
| Q1 25 | 20.9% | 10.9% | ||
| Q4 24 | 21.5% | 16.3% | ||
| Q3 24 | 22.7% | 14.3% | ||
| Q2 24 | 18.6% | 12.4% | ||
| Q1 24 | 19.7% | 6.8% |
净利率HLIRVTY
| Q4 25 | 16.3% | 12.7% | ||
| Q3 25 | 17.0% | 6.7% | ||
| Q2 25 | 16.1% | 7.5% | ||
| Q1 25 | 18.3% | 6.4% | ||
| Q4 24 | 15.0% | 13.0% | ||
| Q3 24 | 16.3% | 13.8% | ||
| Q2 24 | 17.3% | 8.0% | ||
| Q1 24 | 15.6% | 4.0% |
每股收益（稀释后）HLIRVTY
| Q4 25 | $1.70 | $0.86 | ||
| Q3 25 | $1.63 | $0.40 | ||
| Q2 25 | $1.42 | $0.46 | ||
| Q1 25 | $1.76 | $0.35 | ||
| Q4 24 | $1.39 | $0.77 | ||
| Q3 24 | $1.37 | $0.77 | ||
| Q2 24 | $1.30 | $0.45 | ||
| Q1 24 | $1.18 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.3B | $7.3B |
| 总资产 | $3.9B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HLIRVTY
| Q4 25 | $1.1B | $919.9M | ||
| Q3 25 | $923.6M | $931.4M | ||
| Q2 25 | $793.8M | $991.8M | ||
| Q1 25 | $971.0M | $1.1B | ||
| Q4 24 | $799.3M | $1.2B | ||
| Q3 24 | $691.4M | $1.2B | ||
| Q2 24 | $449.7M | $2.0B | ||
| Q1 24 | $721.2M | $1.7B |
股东权益HLIRVTY
| Q4 25 | $2.3B | $7.3B | ||
| Q3 25 | $2.2B | $7.4B | ||
| Q2 25 | $2.2B | $7.6B | ||
| Q1 25 | $2.2B | $7.6B | ||
| Q4 24 | $2.1B | $7.7B | ||
| Q3 24 | $2.0B | $7.9B | ||
| Q2 24 | $1.8B | $7.9B | ||
| Q1 24 | $1.8B | $7.8B |
总资产HLIRVTY
| Q4 25 | $3.9B | $12.2B | ||
| Q3 25 | $3.8B | $12.1B | ||
| Q2 25 | $3.5B | $12.4B | ||
| Q1 25 | $3.8B | $12.4B | ||
| Q4 24 | $3.5B | $12.4B | ||
| Q3 24 | $3.2B | $12.8B | ||
| Q2 24 | $2.9B | $13.4B | ||
| Q1 24 | $3.2B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $217.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $217.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 30.3% | 21.0% |
| 资本支出强度资本支出/营收 | 0.1% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.87× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $738.9M | $509.4M |
8季度趋势，按日历期对齐
经营现金流HLIRVTY
| Q4 25 | $217.7M | $182.0M | ||
| Q3 25 | $325.0M | $138.5M | ||
| Q2 25 | $-131.6M | $134.3M | ||
| Q1 25 | $358.4M | $128.2M | ||
| Q4 24 | $265.5M | $174.2M | ||
| Q3 24 | $289.2M | $147.9M | ||
| Q2 24 | $-64.5M | $158.6M | ||
| Q1 24 | $225.3M | $147.6M |
自由现金流HLIRVTY
| Q4 25 | $217.0M | $161.8M | ||
| Q3 25 | $322.8M | $120.0M | ||
| Q2 25 | $-144.8M | $115.5M | ||
| Q1 25 | $343.9M | $112.2M | ||
| Q4 24 | $261.7M | $149.8M | ||
| Q3 24 | $278.7M | $125.6M | ||
| Q2 24 | $-75.4M | $136.6M | ||
| Q1 24 | $213.1M | $129.7M |
自由现金流率HLIRVTY
| Q4 25 | 30.3% | 21.0% | ||
| Q3 25 | 49.0% | 17.2% | ||
| Q2 25 | -23.9% | 16.0% | ||
| Q1 25 | 51.6% | 16.9% | ||
| Q4 24 | 41.2% | 20.5% | ||
| Q3 24 | 48.5% | 18.4% | ||
| Q2 24 | -14.7% | 19.7% | ||
| Q1 24 | 40.9% | 20.0% |
资本支出强度HLIRVTY
| Q4 25 | 0.1% | 2.6% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 2.2% | 2.6% | ||
| Q1 25 | 2.2% | 2.4% | ||
| Q4 24 | 0.6% | 3.4% | ||
| Q3 24 | 1.8% | 3.3% | ||
| Q2 24 | 2.1% | 3.2% | ||
| Q1 24 | 2.3% | 2.7% |
现金转化率HLIRVTY
| Q4 25 | 1.87× | 1.85× | ||
| Q3 25 | 2.91× | 2.97× | ||
| Q2 25 | -1.35× | 2.49× | ||
| Q1 25 | 2.94× | 3.03× | ||
| Q4 24 | 2.79× | 1.84× | ||
| Q3 24 | 3.09× | 1.57× | ||
| Q2 24 | -0.73× | 2.87× | ||
| Q1 24 | 2.78× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HLI
| Corporate Finance | $473.7M | 66% |
| Financial Restructuring | $156.3M | 22% |
| Financial Advisory Services | $87.1M | 12% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
